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We identified nine nucleotide differences between the genomes of dengue-2 (DEN-2) 16681 virus and its vaccine derivative,
strain PDK-53. These included a C-to-T (16681-to-PDK-53) mutation at nucleotide position 57 of the 5*-untranslated region,
three silent mutations, and substitutions prM-29 Asp to Val, NS1-53 Gly to Asp, NS2A-181 Leu to Phe, NS3-250 Glu to Val,
and NS4A-75 Gly to Ala. Unpassaged PDK-53 vaccine contained two genetic variants as a result of partial mutation at NS3-
250. We constructed infectious cDNA clones for 16681 virus and each of the two PDK-53 variants. DEN-2 16681 clone-
derived viruses were identical to the 16681 virus in plaque size and replication in LLC-MK2 cells, replication in C6/36 cells,
E and prM epitopes, and neurovirulence for suckling mice. PDK-53 virus and both clone-derived PDK-53 variants were
attenuated in mice. However, the variant containing NS3-250-Glu was less temperature sensitive and replicated better in
C6/36 cells than did PDK-53 virus. The variant containing NS3-250-Val had smaller, more diffuse plaques, decreased
replication, and increased temperature sensitivity in LLC-MK2 cells relative to PDK-53 virus. Both PDK-53 virus and the NS3-
250-Val variant replicated poorly in C6/36 cells relative to 16681 virus. Unpassaged PDK-53 vaccine virus and the virus
passaged once in LLC-MK2 cells had genomes of identical sequence, including the mixed NS3-250-Glu/Val locus. Although
the NS3-250-Val mutation clearly affected virus replication in vitro, it was not a major determinant of attenuation for PDK-
53 virus in suckling mice.
INTRODUCTION DEN viruses of all four serotypes (DEN-1 to -4) are
transmitted to humans primarily by Aedes aegypti mos-
Dengue (DEN) viruses are mosquito-borne pathogens
quitoes in tropical and subtropical regions of the world
of the Flavivirus genus, family Flaviviridae. Flaviviruses
and cause illness, ranging from dengue fever to the
are enveloped RNA viruses 45–50 nm in diameter that
severe and often fatal dengue hemorrhagic fever/den-
contain a single-stranded, positive-sense, capped RNA
gue shock syndrome. Investigators at Mahidol Univer-
genome of approximately 11 kb. The gene organization is
sity in Bangkok, Thailand, have developed four live,
5*-untranslated region (UTR)–capsid (C)–premembrane/
attenuated candidate vaccine viruses, one for each of
membrane (prM/M)–envelope (E)–nonstructural protein
the four DEN serotypes, by serial passage of the parent1 (NS1)–NS2A–NS2B–NS3–NS4A–NS4B–NS5–3*-UTR.
viruses in cell culture (Yoksan et al., 1986; Bhamara-The structural proteins C, M, and E and the nonstructural
pravati et al., 1987; Bhamarapravati and Yoksan, 1989,proteins NS1–NS5 are translated as a large precursor
1990; Vaughn et al., 1996). These are currently the bestpolyprotein molecule from a single, long open reading
live, attenuated vaccine virus candidates for dengueframe in the RNA genome. The individual mature viral
in terms of immunogenic efficacy and lack of reacto-proteins are processed from the polyprotein by both cel-
genicity in humans. The uncloned PDK-53 vaccine vi-lular and virus-specified proteases (Westaway et al.,
rus elicits neutralizing antibodies that last at least 1.51985; Rice et al., 1985; Coia et al., 1988; Speight and
years in adult human volunteers (Bhamarapravati etWestaway, 1989). The virion consists of an icosahedral
al., 1987; Bhamarapravati and Yoksan, 1989; Vaughnnucleocapsid that is surrounded by a cell-derived lipid
et al., 1996). We report here the genomic nucleotidemembrane in which the E and M proteins are embedded.
sequences of the virulent 16681 strain of DEN-2 virus
and its attenuated vaccine derivative, strain PDK-53.
1 The nucleotide sequence data reported in this article have been The PDK-53 vaccine contained two phenotypically dif-
deposited with the GenBank Data Library under Accession Nos.
ferent variants. We constructed full-genome-length, in-U87411 (16681) and U87412 (PDK-53).
fectious cDNA clones for DEN-2 16681 virus and each2 To whom correspondence and reprint requests should be ad-
dressed. Fax: (970) 221-6476. E-mail: rmk1@cdc.gov. variant in the PDK-53 vaccine.
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MATERIALS AND METHODS ning at nt 10723) was engineered at the 3* terminus of
the genomic cDNA to permit linearization prior to RNA
Viruses transcription. Amplified cDNA was cloned into a TA vec-
tor (pGEM-T; Promega) by using electroporation-compe-The DEN-2 parental 16681 virus was isolated in 1964
tent Escherichia coli XL1-Blue cells (Stratagene) pre-from the serum of a DHF/DSS patient in Bangkok, Thai-
pared by the method of Dower et al. (1988). Cells wereland (Halstead and Simasthien, 1970). It was passaged
transformed by electroporation (Bio-Rad gene pulser setseveral times in grivet monkey kidney BS-C-1 cells (Hal-
at 2.5 kV, 25 mF, and 200 ohms) and plated on YT agarstead and Simasthien, 1970), six times in rhesus monkey
(Sambrook et al., 1989) containing 80 mg/ml ampicillin.kidney LLC-MK2 cells, once in a rhesus macaque mon-
Plasmid DNA was extracted from cell cultures by thekey, twice in Toxorhynchites amboinensis mosquitoes,
alkaline-sodium dodecyl sulfate (SDS) procedure of Birn-and then 53 times in primary dog kidney (PDK) cell cul-
boim and Doly (1979).ture to derive the PDK-53 vaccine virus (Halstead et al.,
Automated sequencing was performed as recom-1970; Halstead and Simasthien, 1970; Vaughn et al.,
mended (Applied Biosystems/Perkin–Elmer). Both strands1996). Except as noted, the PDK-53 virus was not pas-
of the cDNA were sequenced. The 5*- and 3*-terminal se-saged further in the present study; cDNA for the PDK-53
quences of the genomes of 16681 and PDK-53 viruses wereinfectious clone was amplified directly from the PDK-53
determined with the 5* RACE kit (GIBCO BRL) and by tailingvaccine, Lot 1, manufactured on April 8, 1983. Following
the genomic RNA with poly(A) using E. coli poly(A) polymer-the aforementioned mosquito passages, the 16681 virus
ase as recommended (GIBCO BRL). RT/PCR amplificationseed used here was passaged once in primary green
of the 3* end was performed with virus-specific and oli-monkey kidney cells, twice in LLC-MK2 cells, and four
go(dT) primers.times in Aedes albopictus C6/36 mosquito cells. The
16681 and PDK-53 seeds contained 7.8 1 107 and 3.4 1
Construction of DEN-2 infectious cDNA clones104 PFU/ml, respectively, as determined by plaque titra-
tion in Vero cell monolayers. The 16681 clone was constructed first. Three interme-
diate clones containing nt regions 1–1380 (F1, SstI/SphI),
Cell culture
1380–4493 (F2, SphI/KpnI), and 4493–10723 (F3, KpnI/
XbaI) were constructed in the polylinker site of pUC19.Viruses were grown in baby hamster kidney (BHK-21,
The HindIII/AvaI region of pBR322 was replaced with theclone 15), LLC-MK2 (CCL-7; American Type Culture Col-
57-bp HindIII/EcoRI polylinker site of pUC19 (AvaI andlection), Vero, and C6/36 cells in Eagle’s minimal essen-
EcoRI sites were blunt-ended with Klenow). The SphI sitetial medium containing antibiotic and 5% fetal bovine
was removed by sequential treatment with SphI, T4 DNAserum (FBS). Plaque titrations were performed in Vero
polymerase, and ligase to produce plasmid pBRUC-139S.or LLC-MK2 cell monolayers grown in plastic six-well
DEN-2 16681 F3 cDNA was cloned into the KpnI/XbaItrays. To evaluate plaque size, virus-infected LLC-MK2
sites of pBRUC-139S. The full-genome-length cDNAmonolayers were fixed with 2 ml of 3.7% (v/v) formalde-
clone, pD2/IC-30P (‘‘P’’ for parent virus), was constructedhyde solution in phosphate-buffered saline for 2 hr. The
by ligating the SstI–F1–SphI / SphI–F2–KpnI / KpnI –agar overlay was removed, and the cells were stained
F3–pBRUC–139S–SstI DNAs. PDK-53 virus-specific in-with 1.25% (w/v) crystal violet for 2 min.
fectious clones, pD2/IC-130V (‘‘V’’ for vaccine virus) were
Cloning and sequencing of DEN-2 cDNA constructed by substituting regions of pD2/IC-30P with
cognate cDNA derived from PDK-53 virus. All infectious
Genomic RNA was extracted from virus seed as de-
clone plasmids were electroporated and replicated in E.
scribed by Lewis et al. (1992). Primer sequences were
coli XL1-Blue cells, except for pD2/IC-130V-F, which was
obtained from the published data of Blok et al. (1992).
derived in E. coli TB-1 cells. Plasmid pD2/IC-30P-A2 was
The reverse transcriptase/polymerase chain reaction
derived by a single TB-1 passage of the original pD2/IC-
(RT/PCR) was performed as described by Chang et al.
30P-A clone.
(1995) and using the Taq Extender PCR additive as rec-
ommended (Stratagene). Six overlapping cDNA frag- DEN-2 genomic mRNA transcription and transfection
ments containing genome nucleotide (nt) regions 1–1380
(SphI site), 1380–2676 (HpaI), 2676–4493 (KpnI), 4493– For RNA transcription, plasmids were linearized with
XbaI, treated with 400 mg/ml proteinase K (Fisher Scien-6646 (NheI), 6646–9719 (BspHI), and 9719–10723 (XbaI)
were amplified. Restriction sites SstI and MluI and the tific) for 1 hr at 377, extracted twice with phenol:chloro-
form:isoamyl alcohol (25:24:1; AMRESCO) and once withpromoter (5*-AAATTTAATACGACTCACTATA-3*) for T7
RNA polymerase (Milligan et al., 1987) were engineered chloroform, and then ethanol precipitated. XbaI lineariza-
tion should result in an additional 4 nt at the 3* terminusat the 5* terminus of the cDNA. No extraneous 5* G nt
was inserted between the T7 promoter and the 5*-termi- of the transcribed DEN-2 mRNA, since no effort was
made to blunt-end the linearized DNA with mung beannal A nt of the genomic cDNA. A unique XbaI site (begin-
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nuclease. Genomic mRNA was transcribed from 50– sequences of both viral genomes. DEN-2 16681 virus
contained A at nt 5270, whereas PDK-53 virus contained1000 ng of linearized cDNA template by using a commer-
cial kit (AmpliScribe T7 kit; Epicentre Technologies). Re- a mixture of both T and A at this position. To ensure that
the mixed nt 5270 locus of PDK-53 virus was indicativeactions were incubated for 1.5 hr at 377 in the presence
of 1.6–2.7 mM m7-GpppA cap analog and then used of the vaccine itself, and not the result of the single LLC-
MK2 passage, the relevant vaccine vial-derived ampliconwithout further treatment to transfect BHK-21 cells by
electroporation as described by Liljestro¨m et al. (1991). cDNA was sequenced directly and found to contain the
same mixed A/T profile at nt 5270. Five of seven TAThe transfected cultures were incubated for 6–8 days
at 377, at which time the culture medium was harvested, vector clones containing this amplicon had nt 5270-T,
while two clones had nt 5270-A. These seven clonesclarified by centrifugation, brought to 15% FBS, and
stored in aliquots at 0707. Clone-derived viruses were possessed the PDK-53 virus-specific nt 5547-C, which
clearly indicated that all were derived from the PDK-53passaged once in LLC-MK2 cells before characterization.
vaccine virus.
Analysis of the structural proteins of clone-derived The 9 nucleotide and five encoded amino acid differ-
DEN-2 viruses ences between the genomes of 16681 virus and strain
PDK-53 are summarized in Table 1. Three mutations inVirus structural proteins were visualized by SDS–poly-
the E, NS3, and NS5 genes were silent. A C-to-T (16681-acrylamide gel electrophoresis (SDS–PAGE) (Laemmli,
to-PDK-53) substitution occurred at nt 57 of the 5*-un-1970) of purified virus grown in LLC-MK2 cells. The vi- translated region. The five amino acid mutations includedruses were purified by sedimentation in glycerol/tartrate
prM-29 Asp to Val, NS1-53 Gly to Asp, NS2A-181 Leu togradients (Obijeski et al., 1976). Epitopes were mapped
Phe, NS3-250 Glu to Val, and NS4A-75 Gly to Ala. Theby indirect immunofluorescence assay (IFA; Riggs, 1979)
PDK-53 vaccine virus contained two variants with respectby using a battery of well-defined murine monoclonal
to nt 5270; a significant part of the virus population re-antibodies (MAbs) derived against DEN-2 virus (Henchal
tained the NS3-250-Glu of the parental 16681 virus. Ouret al., 1985). Virus-infected LLC-MK2 cells were fixed in sequence data differed from those reported by Blok etice-cold acetone for 30 min. The MAb preparations were
al. (1992) at 85 nt positions (Fig. 1). They reported 53pretitrated and used at a 1:1000 dilution except for MAb
16681/PDK-53 nucleotide differences (upward-pointing4E5, which was of lower titer and used at a final dilution
solid triangles in Fig. 1), whereas we identified only 9.of 1:40. The MAb binding was detected with a 1:100
Our data agreed with those of Blok et al. (1992) for 6dilution of fluorescein-labeled goat anti-mouse antibody
16681/PDK-53 nucleotide differences (downward-point-(Jackson Immunoresearch Laboratories). Fluorescence
ing triangles).intensity was scored on a 1/ to 4/ scale, with 4/ being
the most intense. All cells were 100% infected, regardless
Derivation of viruses from DEN-2 infectious cDNAof the infecting virus.
clones
Intracranial challenge of newborn mice
Four viruses were derived from 16681-specific cDNA:
Newborn, 1-day-old, or 2-day-old outbred white ICR (1) D2/IC-30P-A virus from the original infectious clone
mice, maintained in a colony at the Centers for Disease (pD2/IC-30P-A) of 16681 virus and a duplicate virus, D2/
Control and Prevention, were challenged intracranially IC-30P-B, from plasmid that was extracted from an inde-
with 104 PFU of virus diluted in 20 ml of diluent. pendent bacterial colony; (2) D2/IC-30P-A2 virus from the
30P-A plasmid that was passaged once in E. coli TB-1
RESULTS cells; (3) D2/IC-30P-A5 virus from the 30P-A plasmid that
was passaged four times in E. coli XL1-Blue cells; andNucleotide sequence analyses of DEN-2 16681 and
(4) D2/IC-30P-A45 (plus duplicate 30P-A49) virus by engi-PDK-53 viral genomes
neering MluI (nt 451, silent A-to-G mutation at nt 453)
and NotI (nt 2269, GA-to-CG [E-445 Gly-to-Ala] mutationAt least two independent clones were sequenced for
each amplified region of the 10,723-nt-long genomes of at nt 2270–2271 and silent T-to-C mutation at nt 2274)
sites into the 30P-A clone with mutagenic amplimers in16681 and PDK-53 (vaccine vial) viruses. Most of the
amplicons contained errors, which were removed during PCR. The entire genomic cDNA sequence of pD2/IC-30P-
A45 was identical to the expected nucleotide sequenceconstruction of the full-genome-length cDNA clones. The
genomes of 16681 and PDK-53 (passaged once in LLC- of pD2/IC-30P-A, except for the engineered mutations.
These mutations were introduced to permit future ex-MK2 cells to increase titer) viruses were also amplified as
10 overlapping fragments by RT/PCR, and both strands of change of the prM and E genes of DEN-2 virus with those
of heterologous flaviviruses.the amplicons were sequenced directly without cloning.
Except for position nt 5270, the sequences obtained by Two variants were derived from PDK-53-specific
cDNA: (1) D2/IC-130Vx-4 (plus duplicate 130Vx-7) virus,this analysis agreed exactly with the cDNA clone-derived
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TABLE 1
Summary of Nucleotide and Amino Acid Sequence Differences between the Genomes of DEN-2 16681 Virus and
Its Vaccine Derivative, Strain PDK-53
Genome Nucleotide Amino acid Amino
nucleotide acid
position 16681 PDK-53 16681 PDK-53 position
57 C T — a — —
524 A T Asp Val prM-29
2055 C T Phe Phe E-373
2579 G A Gly Asp NS1-53
4018 C T Leu Phe NS2A-181
5270 A A/Tb Glu Glu/Valb NS3-250
5547 T C Arg Arg NS3-342
6599 G C Gly Ala NS4A-75
8571 C T Val Val NS5-334
a — , 5*-untranslated region.
b The PDK-53 vaccine contained two genetic variants at genome nucleotide position 5270.
containing eight of the nine mutations in PDK-53 virus of 16681 virus within the 130Vx-4 cDNA background, was
also derived. This virus was essentially identical to the(Table 1) and encoding NS3-250-Glu, and (2) D2/IC-
130Vc-K (plus duplicate 130Vc-C and 130Vc-L) virus, con- 130Vx-4 virus by the phenotypic analyses employed in
this study (data not shown). Only a single silent mutationtaining all nine PDK-53 virus-specific nucleotide muta-
tions, including that encoding NS3-250-Val (Table 1). An occurred in the NheI–XbaI region (Table 1).
Unless specified otherwise, duplicate viruses were es-additional virus, D2/IC-130V-F (plus duplicate 130V-J),
containing the NheI (nt 6646) to XbaI (nt 10723) region sentially identical to their primary clone-derived virus by
FIG. 1. Summary of the nucleotide sequence analyses of the genomes of DEN-2 16681 virus and its vaccine derivative, strain PDK-53. Our data
agreed with those of Blok et al. (1992), except at the 85 nt positions shown. The genomic regions and positions of the relevant nucleotides are
shown above the data determined in the present study (D2-16681.CDC and D2-PDK53.CDC) and by Blok et al. (D2-16681.BLK and D2-PDK53.BLK).
Dots indicate positions of nucleotide identity with the D2-16681.CDC sequence. Upward-pointing solid triangles below the D2-PDK53.BLK sequence
indicate the 53 16681/PDK-53 nucleotide differences reported by Blok et al. (1992). Downward-pointing triangles above the D2-16681.CDC sequence
indicate those positions of 16681/PDK-53 difference at which our data agreed with those of Blok et al. Two variants in the PDK-53 vaccine contained
A or T at nt 5270. The sequences of the PDK-53 virus present in the vaccine vial and after a single passage in LLC-MK2 cells were identical.
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FIG. 2. Plaque phenotypes of DEN-2 16681, D2/IC-30P-A, PDK-53, D2/IC-130Vx-4 (NS3-250-Glu), and D2/IC-130Vc-K (NS3-250-Val) viruses at 9
days postinfection in LLC-MK2 cells. Plaques were recorded by Polaroid photography. Control, uninfected cell monolayer.
the phenotypic analyses employed in this study (data not (type, HI), 4E5 (type, N, HI), 9D12 (subcomplex, N, HI),
13B7 (subcomplex), 1B7 (subcomplex, N, HI), and 4G2shown). All nine virus-specific genetic loci, as well as
silent cDNA artifacts incorporated into the cDNA clones, (group, N, HI), as well as prM-specific MAb 2H2 (com-
plex) reacted identically or nearly identically (scores ofwere confirmed for each clone-derived virus by RT/PCR
and sequencing of appropriate cDNA amplicons. Two 2–4/) with LLC-MK2 cells infected with 16681, 30P-A,
PDK-53, 130V-F (130Vx-4 was not tested), or 130Vc-K vi-silent cDNA artifacts were incorporated into the pD2/IC-
30P clones at nt 1531 (C to T) and nt 2406 (A to G). A rus. The flavivirus group-specific MAb 6B6C-1 (Roehrig
et al., 1983), elicited against St. Louis encephalitis virus,single silent artifact was incorporated into the pD2/IC-
130Vx and pD2/IC-130Vc clones at nt 900 (T to C). also reacted at 3–4/ with these viruses, whereas the
DEN-1 virus-specific MAb 1F1 (Gubler, 1987) had no re-
Analysis of the structural proteins of DEN-2 viruses activity with these viruses (data not shown).
The SDS–PAGE profiles of the structural proteins of
Plaque phenotypes of DEN-2 viruses in LLC-MK2 cellsDEN-2 16681 and D2/IC-30P-A viruses were identical
(data not shown). Authentic expression of the E and prM DEN-2 16681 and D2/IC-30P-A viruses (Fig. 2), as well
as viruses 30P-A2, 30P-A5, and 30P-A45 (not shown),proteins in clone-derived viruses was demonstrated by
MAb mapping of epitopes by IFA. E-specific MAbs (Hen- produced plaques of about 2.5-mm diameter at 9 days
postinfection in LLC-MK2 cells. PDK-53 virus from a vialchal et al., 1985) 3H5 (DEN-2 type-specific, neutralization
[N] and hemagglutination-inhibition [HI] activities), 2H3 of vaccine and 130Vx-4 virus (NS3-250-Glu) produced a
FIG. 3. Growth curves of DEN-2 16681, D2/IC-30P-A, PDK-53, D2/IC-130Vx-4 (NS3-250-Glu), and D2/IC-130Vc-K (NS3-250-Val) viruses in LLC-MK2
cells grown in 75-cm2 tissue culture flasks. The multiplicity of infection was approximately 0.004 PFU/cell.
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mixed, smaller plaque phenotype. D2/IC-130Vc-K virus Neurovirulence of DEN-2 viruses in suckling mice
(NS3-250-Val) produced small, diffuse plaques. Longer
Groups of 16 newborn white ICR mice were inoculated
incubation of 130Vc-K virus in Vero cell monolayers per-
intracranially with 104 PFU of original or clone-derived
mitted better visualization of the virus plaques for pur-
virus. DEN-2 16681 and 16681 clone-derived viruses, ex-
poses of titration (not shown).
cept for 30P-A2 virus, resulted in 50–81% mortality with
an average survival time of 15–17 days (Table 2). Relative
Growth curves of DEN-2 viruses in LLC-MK2 and C6/ to control mice inoculated with diluent, significantly lower
36 cells mean body weights (P  0.001, Student’s t test) were
observed at 28 days postinfection in those mice that
DEN-2 16681 and D2/IC-30P-A viruses (Fig. 3), as well
survived challenge with 30P-A or 30P-A45 virus (weights
as 30P-A2 and 30P-A5 viruses (not shown), grew with
not shown).
nearly equal efficacy in LLC-MK2 cells, reaching peak In a separate experiment, intracranial challenge of 2-
titers of 107 – 108 PFU/ml at 7–10 days postinfection. PDK-
day-old mice (10 mice per group) with 104 PFU of 16681
53 virus (open circles in Fig. 3) from a vial of vaccine,
or 30P-A virus resulted in 80% (average survival time of 15
whose low titer set the low multiplicity of infection of
days) or 90% (average survival time of 17 days) mortality,
0.004 PFU/cell, and PDK-53 clone-derived 130Vx-4 virus
respectively, whereas challenge with 30P-A2 virus re-
(NS3-250-Glu) grew to peak titers of about 107 PFU/ml
sulted in 10% mortality (data not shown). The reduced
at 6–9 days postinfection. The somewhat delayed repli-
mortality caused by the 30P-A2 virus may have been due
cation of PDK-53 virus was evident in a second experi-
to a mutation of pD2/IC-30P-A2 during passage of pD2/
ment as well (not shown). D2/IC-130Vc-K virus (NS3-250-
IC-30P-A in E. coli TB-1 cells. However, the cDNA in
Val) replicated less efficiently, reaching a peak titer of
pD2/IC-30P-A2 has not been sequenced to confirm this
105.0 PFU/ml at 9 days postinfection.
speculation.
PDK-53 virus replicates with much lower efficiency
Except for a single death (at 11 days postinfection) in
than 16681 virus in Ae. aegypti mosquitoes (Khin et al.,
the 130Vc-L group, all of the PDK-53 clone-derived vi-
1994). We investigated virus replication in C6/36 cells
ruses were attenuated for suckling mice by intracranial
(data not shown). DEN-2 16681 and D2/IC-30P-A viruses
inoculation. Results for the 130Vx-4 and 130Vc-K viruses
attained peak titers of 108.3 –108.7 PFU/ml at 7 days postin-
are shown in Table 2. Mice surviving challenge with
fection. PDK-53 clone-derived 130Vx-4 virus (NS3-250-
130V-F, 130V-J, 130Vx-4, and 130Vc-C viruses had lower
Glu) replicated to a peak titer of 106.2 PFU/ml. The 130Vc-
(P  0.05) mean body weights than the control group at
K virus (NS3-250-Val) replicated poorly in C6/36 cells,
28 days postinfection. The 130Vc-L mouse group actually
achieving a peak titer of 104.0 PFU/ml at 7 days postinfec-
had a significantly greater (P  0.05) mean body weight
tion. In the same experiment, the PDK-53 vaccine virus
at 14 days postinfection. Because of low seed virus titer,
had a peak titer of 103.0 PFU/ml. In a separate experiment,
the challenge dose for the 130Vc-L group was 103.8 PFU.
16681, PDK-53, and 130Vc-L viruses attained peak titers
Mice challenged with the LLC-MK2-1 passage of theof 107.5, 103.3, and 102.3 PFU/ml, respectively, at 6–8 days
PDK-53 vaccine virus all survived without significant
postinfection in C6/36 cells (data not shown).
weight loss (Table 2).
Temperature sensitivities of DEN-2 viruses in LLC- DISCUSSION
MK2 cells
We report here the development of infectious cDNA
clones for DEN-2 16681 virus and its vaccine derivative,Viruses were tested for temperature sensitivity in LLC-
MK2 cells. DEN-2 16681 and D2/IC-30P-A virus titers strain PDK-53. The infectious clones of the 17D strain of
yellow fever virus (Rice et al., 1989) and DEN-2 PDK-were reduced by 89–90% at 397, relative to the virus titer
at 377, at 8 days postinfection (Fig. 4). D2/IC-30P-A2 virus 53 virus (reported here) are currently the only flavivirus
infectious clones that have been developed from vaccinehad 83% reduction in titer (not shown). As reported by
Yoksan et al. (1986), virus from the PDK-53 vaccine vial viruses which have been tested in humans. DEN-2 16681
clone-derived D2/IC-30P viruses were identical to thewas temperature sensitive, as indicated by a 99.4% re-
duction in titer at 397. Clone-derived viruses representing 16681 virus in terms of the size of the structural proteins
in the virion, expression of appropriate E and prM epi-the two genetic variants in the PDK-53 vaccine vial
showed different temperature sensitivities. The 130Vx-4 topes, plaque size in LLC-MK2 cells, replication rate in
LLC-MK2 and C6/36 cells, relative lack of temperaturevirus (NS3-250-Glu) was more temperature-sensitive
(97% reduction in titer) than 16681 virus, but less so than sensitivity in LLC-MK2 cells, and, except for the 30P-A2
virus, neurovirulence for suckling mice. Although the 30P-the PDK-53 vaccine virus. The NS3-250-Val variant, repre-
sented by D2/IC-130Vc-K virus, was highly temperature A2 virus was partially attenuated in mice, its replication
phenotype in vitro was identical to that of the 16681 virus.sensitive, with 99.98% reduction of virus titer at 397 rela-
tive to the virus titer at 377. We speculate that plasmid pD2/IC-30P-A2 may have ac-
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FIG. 4. Temperature sensitivities of DEN-2 16681, D2/IC-30P-A, PDK-53, D2/IC-130Vx-4 (NS3-250-Glu), and D2/IC-130Vc-K (NS3-250-Val) viruses
in LLC-MK2 cells grown in 75-cm2 flasks at 37 or 397. Cell culture media were harvested at 8 days postinfection and titrated in Vero cell monolayers.
The bar heights and the numerical values over the bars indicate the percentage of virus replication at 397 relative to that at 377 ([virus titer at 397/
virus titer at 377] 1 100). The multiplicity of infection was approximately 0.004 PFU/cell.
crued a mutation during passage of pD2/IC-30P-A in E. mixture of two phenotypically different variants as a result
of partial mutation at NS3-250. Since both of the PDK-53coli TB-1 cells.
clone-derived variants were attenuated for newbornWe identified only 9 nucleotide mutations between the
mice, the NS3-250 Glu-to-Val (16681-to-PDK-53) mutation16681 and the PDK-53 genomes. These data differed at
is not a major determinant of attenuation for PDK-53 virus85 nt positions from the data of Blok et al. (1992), who
in mice. However, this mutation clearly affected virusreported 53 nucleotide differences for this virus pair. Our
replication in vitro, as demonstrated by the alteredresults showed that the PDK-53 vaccine vial contains a
plaque phenotype and increased temperature sensitivity
in LLC-MK2 cells and the decreased replication rate in
TABLE 2 both LLC-MK2 and C6/36 cells of the NS3-250-Val variant.
The NS3-250 mutation may affect the proteinase or heli-Neurovirulence of DEN-2 Viruses in Newborn White ICR Mice
Following Intracranial Challenge with 104 PFU of Virus case activity of the conformationally mature NS3 protein
of PDK-53 virus, although this mutation does not occur
Average at the putative sequence motifs for these NS3 activities
survival
(Gorbalenya et al., 1989a,b; Wengler et al., 1991; Cham-time
bers et al., 1991; Wengler and Wengler, 1991; Pause andPercentage
Sonenberg, 1992; Arias et al., 1993; Warrener et al., 1993).Virus mortalitya Days (SD)
The relative contribution of each of the two PDK-53 vari-
Diluent 0.0 — b ants to the infectivity and immunogenic efficacy of the
16681c 81.25 15.6 (2.1) PDK-53 vaccine virus administered to humans is un-30P-A 50.0 16.8 (5.4)
known.30P-Bd 75.0 15.3 (1.0)
Although the E protein of flaviviruses often encodes30P-A2 25.0 14.0 (2.2)
30P-A5 68.75 15.5 (1.2) determinants of attenuation and virulence (Barrett et al.,
30P-A45 68.75 15.0 (1.7) 1990), we identified no amino acid substitutions in the E
30P-A49d 81.25 15.6 (1.0) protein of PDK-53 virus. The attenuation of PDK-53 virus
130Vx-4 0.0 —
is probably due to one or more of the mutations at 5*-130Vc-K 0.0 —
UTR-57, prM-29, NS1-53, NS2A-181, and NS4A-75. MajorPDK-53c 0.0 —
determinants of attenuation have been shown to reside
a (Number of deaths/16 mice per group) 1 100. in the 5*-UTR of other positive-stranded viruses, including
b —, not applicable. the Sabin poliovaccine viruses (Evans et al., 1985; Mac-c Wild-type DEN-2 16681 and PDK-53 viruses. The PDK-53 vaccine
adam et al., 1994) and the TC-83 vaccine strain of Vene-virus was passaged once in LLC-MK2 cells to increase the virus titer
zuelan equine encephalitis virus (Kinney et al., 1993).for this experiment. All other viruses are clone-derived, D2/IC viruses.
d Duplicate of the preceding, primary clone-derived virus. Cahour et al. (1995) demonstrated profound effects, in-
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derivative: Sequence relationships with the flaviviruses and othercluding decreased growth in LLC-MK2 and C6/36 cells,
viruses. Virology 187, 573–590.of deletions engineered into the 5*-UTR of DEN-4 virus
Bray, M., and Lai, C.-J. (1991). Construction of intertypic chimeric den-variants. Analyses of recombinant polio type I viruses gue viruses by substitution of structural protein genes. Proc. Natl.
obtained from infectious cDNA clones demonstrated that Acad. Sci. USA 88, 10342–10346.
loci involved in attenuation were distributed in several Bray, M., Men, R., and Lai, C.-J. (1996). Monkeys immunized with in-
tertypic chimeric dengue viruses are protected against wild-type vi-regions of the genome and that alterations in antigenicity
rus challenge. J. Virol. 70, 4162–4166.correlated poorly with virulence changes (Omata et al.,
Cahour, A., Pletnev, A., Vazeille-Falcoz, M., Rosen, L., and Lai, C.-J.1986).
(1995). Growth-restricted dengue virus mutants containing deletions
Since no amino acid mutations occurred in the C, M, in the 5* noncoding region of the RNA genome. Virology 207, 68–
and E structural genes of PDK-53 virus, the infectious 76.
Chambers, T. J., Grakoui, A., and Rice, C. M. (1991). Processing of theclones of the two PDK-53 variants might be useful ge-
yellow fever virus nonstructural polyprotein: A catalytically active NS3netic backgrounds for the expression of the structural
proteinase domain and NS2B are required for cleavages at dibasicgenes of other DEN virus serotypes or other flavivir-
sites. J. Virol. 65, 6042–6050.
uses. Such chimeric viruses would be expected to re- Chang, G.-J. J., Cropp, B. C., Kinney, R. M., Trent, D. W., and Gubler,
tain the PDK-53 determinants of attenuation. The engi- D. J. (1995). Nucleotide sequence variation of the envelope protein
neering of intertypic DEN chimeras within the genetic gene identifies two distinct genotypes of yellow fever virus. J. Virol.
69, 5773–5780.background of DEN-4 virus has been reported (Bray
Chen, W., Kawano, H., Men, R., Clark, D., and Lai, C.-J. (1995). Construc-and Lai, 1991; Chen et al., 1995; Bray et al., 1996). The
tion of intertypic chimeric dengue viruses exhibiting type 3 antigenic-contribution of the prM-29 Asp-to-Val mutation to the
ity and neurovirulence for mice. J. Virol. 69, 5186–5190.
attenuated phenotype of PDK-53 virus may be im- Coia, G., Parker, M. D., Speight, G., Byrne, M. E., and Westaway, E. G.
portant. We plan to investigate chimeric viruses de- (1988). Nucleotide and complete amino acid sequences of Kunjin
virus: Definitive gene order and characteristics of the virus-specifiedrived from genetic exchanges between DEN-2 16681
proteins. J. Gen. Virol. 69, 1–21.and PDK-53 viruses to define the genetic loci that en-
Dower, W. J., Miller, J. F., and Ragsdale, C. W. (1988). High efficiencycode the attenuated phenotype of the vaccine virus.
transformation of E. coli by high voltage electroporation. Nucleic
Acids Res. 16, 6127–6145.
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